With consumers seeking high-quality products that deliver real health benefits, start to re-imagine your products with Veri-te™ resveratrol. Learn about the cutting-edge clinical trials with Veri-te™ resveratrol on cognitive, bone and gut health.
Resveratrol has earned attention both in the media and with scientists around the world due to the significant body of published studies showing its beneficial support in cardiovascular health. It continues to remain the focus in many clinical studies including some cutting edge fields such as cognitive health, bone health and gut health.
The 5th International Conference on Resveratrol and Health was held on October 18th-20th, 2018 in Xi’an, China. This conference is the leading annual knowledge sharing event for the global resveratrol community. Evolva’s Veri-te™ resveratrol is committed to the advancement of the science behind resveratrol to bring innovative products to the market and we were proud to be a sponsor of Resveratrol 2018.
“At Evolva, we are committed to supporting clinical trials and research innovations that help our partners reimagine the potential health benefits of resveratrol,” said Sally Aaron, SVP Health Ingredients and Marketing at Evolva. “Resveratrol 2018 is such an important conference for us to support because it highlights the wealth of new research on resveratrol across a number of new benefits areas, like bone health. The versatility of resveratrol continues to be supported by a strong scientific foundation.”
Among the seventeen independent research groups who presented their findings during the three-day event, four are currently conducting trials using Veri-te™ resveratrol. Among these are Peter Howe, PhD, Emeritus Professor of Clinical Nutrition at the University of Newcastle, Australia who presented preliminary data from the longest randomized crossover trial using resveratrol supplementation to be undertaken in postmenopausal women, involving some 140 participants over two years. Amongst the primary outcomes are cerebrovascular responsiveness and cognitive performance but the long intervention periods and cross over design allows for the detection of bone mineral density and total body composition using DEXA scanning.
Preliminary results provided from an interim evaluation after 12 months (halfway) in to the trial were presented at the conference and revealed significant benefits of 75 mg of Veri-te™ resveratrol taken twice daily compared to placebo. Headline results indicated that resveratrol treatment reduced the loss of bone mineral density in the neck of the femur resulting in a 12% improvement in the FRAX t-score (a Fracture Risk Assessment tool), a 36% reduction in hip fracture risk and a 9% reduction in the 10 year risk of a major osteoporotic fracture. Although lean mass was not affected by resveratrol intake, there was a tendency for hand grip strength to increase by 2.9%. These promising results are expected to become more significant by intra-individual comparisons afforded by the crossover at 12 months, although the benefits of resveratrol supplementation in postmenopausal women are already clearly evident.
Also presenting at the conference was Scott Boyer, founder and scientific advisor at Nutrinovate AB, Sweden 
who presented the results on the plasma exposure of resveratrol (bioavailability) as delivered to the lining of the mouth from Nutrinovate’s award winning Reserol product. This uses their Functional Film Technology™ with Veri-te™ resveratrol. The uptake of resveratrol via the oral mucosa is radically different from the absorption of capsules, tablets, liquid shots and other orally dissolvable formulations absorbed via the gut and the product was shown to increase the overall plasma exposure of total resveratrol (free resveratrol and its main metabolites) by 3.5 fold in healthy volunteers using a cross-over design. Nutrinovate’s Reserol product is the winner of the ‘Editor’s Award for Innovation’ category at the NutraIngredients Awards 2018 and ‘Editor’s Award for Functional Food Innovation’ at the NutraIngredients Asia Award 2018 in Singapore.
Evolva have also teamed up with Dr Emma Wightman at Northumbria University’s Brain, Performance and Nutrition Research Centre to look at the effects of resveratrol supplementation on gut microbiota, systemic inflammation and brain function using Veri-te™ resveratrol. Published research has shown resveratrol’s benefits on blood flow, cardiovascular health and cognitive function. This study will look at the interaction of resveratrol on gut microbiota, and join a growing body of studies showing consuming resveratrol can positively benefit gut microbiota.
Veri-te™ resveratrol has been chosen by these leading research groups as a trusted source of high quality and contaminant-free trans-resveratrol. Together with consistency, stock reliability and price stability it is also becoming the chosen source for many new product developments and food supplement reformulations across Europe and the US.
Evolva will be exhibiting at HI Europe in Frankfurt on the 27th – 29th of November showcasing its new Veri-te™ resveratrol CWD 90, using LipiSperse® Dispersion Technology. With a 90% trans-resveratrol content, this unique ingredient system is designed to deliver a large amount of resveratrol into aqueous environments in a simple, effective way. With a neutral taste and enhanced bioavailability, the possibilities are endless for innovative delivery opportunities.
Visit us at stand 8M89 to learn more.
